Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
NCT03535350Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Aug 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ibrutinib in glioblastoma (GBM) (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Maximum tolerated dose of ibrutinib at 6 weeks. Started Aug 2018; status: completed.
02
Drugs
ibrutinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03535350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535350.